Incretin-based drugs not associated with greater heart failure hospitalization risk than other drug combos in retrospective study
Researchers compared patients taking dipeptidyl peptidase 4 (DPP-4) inhibitors and glucagon-like peptide 1 (GLP-1) analogues to those taking 2 or more oral antidiabetic drugs.
Researchers used data from the ADVANCE-ON study to develop the AD-ON risk score, a 10-year risk score for the combined endpoint of major cardiovascular disease (CVD) or chronic kidney disease.
The warnings are based on a review finding 73 cases of ketoacidosis in patients with type 1 or type 2 diabetes and 19 cases of life-threatening urosepsis and pyelonephritis.
Compared to matched controls, patients on metformin monotherapy did not show significant excess mortality during follow-up, but patients on sulfonylurea or insulin monotherapy had higher mortality rates.
The industry-funded, double-blind, randomized, controlled trial assigned adult patients with type 2 diabetes who were not taking antihyperglycemic agents before the study to 26 weeks of treatment in 1 of 5 arms.
The population-based prospective cohort analysis of adults who were members of a single U.S. health care delivery system compared CHD risk among those with and without a history of diabetes or CHD.
A “virtual clinic” model involving consultations between diabetes subspecialists and primary care physicians was associated with glycemic improvements in treated patients and controls from the same practices, a British study found.
The authors stated that the impact of prediabetes awareness on the odds of adopting risk-reducing lifestyle factors highlights the special influence of physician input on patient behavior.“ Increasing patients' awareness
Once-weekly glucagon-like peptide 1 (GLP-1) receptor agonists lower HbA1c without increasing body weight, a review found.
Patients who were under age 55 faced a more substantial increase in mortality risk from having diabetes than older patients.